We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Easy-To-Use Point-Of-Care Testing Device Accurately Measures Cortisol Levels in Blood

By HospiMedica International staff writers
Posted on 04 Sep 2024

Stress manifests in various forms, and the inability to manage high stress levels can lead to severe health problems like depression and Alzheimer's disease. More...

The development of a cost-effective, reproducible, and easy-to-use point-of-care testing device that accurately measures cortisol—a key stress biomarker in the blood—has been a significant goal of researchers. Such a device could greatly facilitate the quick diagnosis of elevated cortisol levels, thereby significantly enhancing quality of life. However, the electrodes used in currently available devices are not stable under varying conditions such as changes in pH and temperature, resulting in a limited shelf life and difficulties in commercial production.

Now, researchers at Xi'an Jiaotong-Liverpool University (XJTLU, Suzhou, China) have developed an innovative cortisol detector that addresses these challenges. Traditional cortisol sensors use reference electrodes with a silver layer that tends to oxidize and destabilize during electrochemical measurements. In the new study published in the journal Talanta, the researchers introduced iridium oxide nanoparticles to coat the silver layer, significantly enhancing the stability, sensitivity, and reproducibility of cortisol measurements in point-of-care settings. This is the first application of iridium oxide in this manner. The resulting device is simple and affordable, capable of detecting cortisol levels at concentrations 3,000 times lower than the typical cortisol range found in blood, making it highly suitable for commercial use. Additionally, the iridium oxide-modified electrodes have increased the selectivity of the tests, improving the device’s overall efficacy.

"One problem with the current solutions is that there is much similarity between cortisol and other hormones such as progesterone, testosterone, and corticosterone. This means it is difficult for the detectors to tell them apart,” said Dr. Graham Dawson, XJTLU Associate Professor and co-author. “Our iridium oxide-modified electrode is selective enough to distinguish the different hormones and helps to solve this issue."

Related Links:
XJTLU


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.